United Therapeutics grants equity to director Mesa

United Therapeutics Corporation director Nilda Mesa received annual non-employee director equity awards on July 22, 2026, consisting of 380 restricted stock units and 1,190 stock options.

Rhea-AI Filing Summary

United Therapeutics Corporation director Nilda Mesa received annual non-employee director equity awards on July 22, 2026, consisting of 380 restricted stock units and 1,190 stock options. Each restricted stock unit represents the right to receive one common share upon vesting. The options carry a $527.0700 exercise price and, together with the RSUs, are scheduled to become fully vested on the earlier of the one-year anniversary of the grant date or the next Annual Meeting of Shareholders, anticipated for June 25, 2027. After these awards, Mesa directly holds 5,678 shares of United Therapeutics common stock.

Insider Trade Summary

Grant/Award: 1,570 shares

Grant/Award 3 txns

Insider Mesa Nilda

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit F1, F2, F3, F4	380	$0.00	$0.00
Grant/Award	Stock Option F2, F3	1,190	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Restricted Stock Unit — 380 contracts (Direct); Stock Option — 1,190 contracts (Direct); Common Stock — 5,678 shares (Direct)

Footnotes (4)

1. F1. Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.
2. F2. Annual non-employee director award.
3. F3. Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.
4. F4. Not applicable as restricted stock units do not have an expiration date.

Key Figures

Restricted stock units granted: 380.0000 units Stock options granted: 1190.0000 options Option exercise price: $527.0700 per share +3 more

6 metrics

Restricted stock units granted 380.0000 units Annual non-employee director RSU award on July 22, 2026

Stock options granted 1190.0000 options Annual non-employee director stock option award on July 22, 2026

Option exercise price $527.0700 per share Exercise price of 1,190 stock options granted to Nilda Mesa

Option expiration date 2033-07-22 Expiration date of the director stock option award

Award vesting reference date 2027-06-25 Anticipated date of next Annual Meeting for full vesting of awards

Common shares held after awards 5678.0000 shares Direct ownership of United Therapeutics common stock after July 22, 2026 awards

Key Terms

Restricted Stock Unit, Stock Option, Annual non-employee director award, Annual Meeting of Shareholders

4 terms

Restricted Stock Unit financial

"Each restricted stock unit represents the right to receive, following vesting, one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Stock Option financial

"Stock Option representing the right to acquire shares of common stock"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Annual non-employee director award financial

"Annual non-employee director award."

Annual Meeting of Shareholders regulatory

"the date of the next Annual Meeting of Shareholders following the grant date"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did United Therapeutics (UTHR) grant to director Nilda Mesa?

United Therapeutics granted director Nilda Mesa 380 restricted stock units and 1,190 stock options as annual non-employee director awards on July 22, 2026. Each RSU converts into one common share, and the options relate to an equal number of common shares at a set exercise price.

When do Nilda Mesa’s new United Therapeutics (UTHR) director awards vest?

The awards are expected to fully vest on the earlier of one year after the grant date or the date of the next Annual Meeting of Shareholders. The anticipated date of that meeting is June 25, 2027, which serves as the current vesting reference.

What is the exercise price and term of Nilda Mesa’s new United Therapeutics (UTHR) stock options?

Mesa received 1,190 stock options with an exercise price of $527.0700 per share. These options are tied to United Therapeutics common stock, vest on the same schedule as the RSUs, and are scheduled to expire on July 22, 2033 if not exercised earlier.

How many United Therapeutics (UTHR) shares does Nilda Mesa own after these awards?

Following the reported equity grants, Nilda Mesa directly holds 5,678 shares of United Therapeutics common stock. This reported total reflects her direct ownership position as of July 22, 2026, separate from the additional shares underlying the new RSUs and stock options.

Were Nilda Mesa’s United Therapeutics (UTHR) equity awards made under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not checked, indicating these equity awards were not reported as made pursuant to a Rule 10b5-1 trading plan. They are described instead as annual non-employee director awards granted on the stated grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/23/2026 - 04:43 PM Accepted by SEC EDGAR 07/23/2026 - 04:43 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mesa Nilda

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MARYLAND 20910

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								5,678	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	$0.00(1)	07/22/2026		A		380(2)		06/25/2027(3)	(4)	Common Stock	380	$0.00	380	D
Stock Option	$527.07	07/22/2026		A		1,190(2)		06/25/2027(3)	07/22/2033	Common Stock	1,190	$0.00	1,190	D

Explanation of Responses:

1. Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

2. Annual non-employee director award.

3. Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.

4. Not applicable as restricted stock units do not have an expiration date.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	07/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)